XARELTO®: Stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)

Proven once-daily,* 24-hour stroke risk reduction1,2

*Taken with evening meal.

Demonstrated clinical outcomes in an obesity subgroup and consistent real-world evidence in patients who have NVAF and morbid obesity3,4

NVAF DOSING Once-daily dosing*

NVAF EFFICACY Proven once-daily,* 24-hour stroke risk reduction1,2

NVAF SAFETY Proven safety profile1

NVAF CLINICAL TRIALS Consistent outcomes in a subgroup analysis of patients who have NVAF and morbid obesity4

FORMULARY FINDER Coverage for your patients

JANSSEN CAREPATH XARELTO® Savings Program

NVAF Resources

DOSING ACROSS INDICATIONS Condition-specific dosing for XARELTO®

ROCKET AF REPRINT Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial

NVAF WELCOME KIT Your patient’s guide to starting treatment

View all resources

NVAF = nonvalvular atrial fibrillation.

References: 1. Patel MR, Mahaffey KW, Garg J, et al; and the ROCKET AF Steering Committee, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. 2. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421. 3. Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial). Am J Cardiol. 2017;119(12):1989-1996. 4. Peterson ED, Ashton V, Chen Y-W, Wu B, Spyropoulos AC. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J. 2019;212:113-119.